Skip to main content

Advertisement

Advertisement

Business

Lonza invests in new production line in China

Lonza invests in new production line in China

FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann

ZURICH : Lonza is investing in new drug product manufacturing capacity at its site in Guangzhou, China, the Swiss company said on Monday.

The sterile, multi-product fill and finish line is expected to be completed in 2022 and will create more than 150 jobs. Lonza, which has been making ingredients for Moderna's COVID-19 vaccine, did not say how much it was spending on the Guangzhou plant.

(Reporting by John Revill; Editing by Michael Shields)

Source: Reuters

Advertisement

Also worth reading

Advertisement